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 Gastrointestinal (GI)  cancers are known  as  
malignant situations of the GI system and related 
organs with digestion including the esophagus, 
stomach, liver, pancreas, small intestine, colon and 
rectum which are responsible for more cancers and 
more deaths from cancer than any other system in 
the body (1, 2). Use of traditional medicine for 
cancer treatment is usually free of side effects and 
generally inexpensive (3). Nigella sativa (N. sativa) 
as a herbal plant of the Ranunculaceae family has a 
long-term history in different medicinal and 
nutritional goals and is growing in Southwest Asia, 
 Gastrointestinal (GI) cancers are known as malignant condition of 
the GI system associated with the organs which have role in 
digestion. More cancers and more deaths from cancer are related to 
the cancers occurred in this system. Nigella sativa (N. sativa) seeds 
which are traditionally used as a food additive, preservative or a 
spice in many cultures, has been considered for treatment of 
various diseases. Thymoquinone (TQ) is the main bioactive 
component of the volatile oil of N. sativa seeds. Therapeutic 
effects of TQ for treatment of various diseases such as cancers, in 
both in vivo and in vitro conditions, have recently been interested.  
In this comprehensive review, we summarized the new studies 
related to anti- cancer activity of TQ associated with its possible 
mechanisms  in GI  cancers including oral cancer, esoghageal 
cancer, gastric cancer, colorectal cancer and also liver and 
pancreatic cancers.  It is concluded that TQ could be considered as 
an anticancer agent alone or in combination with chemotherapeutic 
drugs in treatment of GI tract cancers, however well designed 
clinical trials in humans are required to confirm these effects. 
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southern Europe and North Africa (4). The seed is 
named black seed or black cumin in English. Black 
seed consists of over 100 valuable components. It 
is a rich source of carbohydrates, proteins, essential 
fatty acids, minerals and vitamins (5-7). 
Thymoquinone (TQ) as the main component of 
volatile oil extracts of N. sativa, has recently been 
considered for its antioxidant, immunoprotective 
and antitumor features (8-11). Using of a 
combination of dietary phytochemicals with 
different mechanisms has been explained as a 
favorable approach to monitoring of various 
cancers with side effects. It has been reported some 
effects of TQ on cancer cells contains DNA injury, 
cell cycle arrest, reactive oxygen species (ROS) 
dependent apoptosis and decreased cell 
proliferation (10, 12). The present review provides 
the recent studies from 2004 to 2018 that regarding 
the anti cancer activity and related mechanisms of 
TQ in GI cancers.  
Methods 
Pubmed, google scholar and science direct 
databases were searched from 2004 until 2018. The 
keywords used were the following terms: 
thymoquinone, gasterointestinal cancer, hepatic 
cancer and pancreatic cancer. Searching was done 
on articles with English language.  
Results  
Oral and esophageal cancer 
Oral cancer is an usual tumor which can be 
accompanied with high morbidity and death. P38 
mitogen-activated protein kinase (MAPK) has role 
in cell proliferation and differentiation.  The study 
was done by Abdelfadil et al. showed that 
thymoquinone can cause to apoptosis in oral cancer 
cells through downregulation of p38β MAPK (13). 
Hu  et al. explored the chemosensitive property and 
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mechanism of TQ in increasing effect of cisplatin 
(DDP)-induced apoptosis of esophageal carcinoma 
(EC) both in vitro and in vivo. Based on the in vivo 
and in vitro results, TQ enhanced chemosensitivity 
and cellular apoptosis of DDP via blocking the 
activation of Janus kinas 2/ Signal transducer and 
activator of transcription 3 (JAK2/STAT3) way. 
According to this study, TQ with DDP may 
interfere the development of EC and can be 
considered as a chemotherapeutic agent in EC 
(14). 
Gastric cancer 
Gastric cancer is the third causing of death related 
to cancer worldwide. In spite of reducing in its 
occurrence in some areas of the world, this cancer 
is still considered as a main clinical challenge 
related to delay in diagnosis with a weak 
prognosis and little treatment choices (15).  5-
fluorouracil (5-FU) is the most common 
chemotherapeutic agent in stomach cancer alone or 
composed with other cytotoxic drugs (16, 17). 
Lei et al. for the first time investigated the 
chemosensitizing property of TQ and 5-FU on 
gastric cancer cells in vitro and in vivo. The results 
showed that pretreatment with TQ importantly 
elevated the apoptotic features in gastric cancer 
cell lines induced by 5-FU in vitro. Furthermore, 
its found that TQ increased the 5-FU-induced 
death of gastric cancer cells through decreasing of 
B-cell lymphoma 2 (Bcl-2) as the anti-apoptotic 
protein, the increasing of bax as the pro-apoptotic 
protein, and caspase-3 and caspase-9 activation.  
Furthermore, combined treatment of TQ with 5-FU 
showed an importantly more effective antitumor 
effect than each of them alone in a xenograft tumor 
mouse model. This study suggested that the TQ/5-
FU combined treatment causes apoptosis through 
increasing of caspase-3 and caspase-9 activation in 
gastric cancer cells (18).  
To find the mechanism of apoptosis induce by TQ 
in human gastric cancer cells in vitro and in vivo, 
the cultured HGC27, BGC823, and SGC7901 cells 
treated with TQ (0, 10, 25, 50, 75, 100, 125 μmol/
L) for 12 h, 24 h, and 36 h. TQ caused to apoptotic 
cell death in HGC27 cells in dose dependent 
manner.  TQ prevented the STAT3 but not STAT5 
phosphorylation. In addition, TQ decreased the 
STAT3-regulated genes expression including 
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cyclin D, survivin, Bcl-2, and VEGF, and 
activated caspase-3,7,9. Similar to the in vitro 
results, TQ was greatly effective as an antitumor 
agent in a xenograft tumor in mice model (19). 
Colorectal cancer 
Colorectal cancer (CRC) is one of the most usual 
cancers with high mortality rate. This cancer can 
cause to 0.5 million deaths each year. To fight this 
type of cancer, the increase of novel particular 
drug candidates is required. Non sensitivity and 
narrow therapeutic properties of its common 
chemotherapeutic drug show a great problem in 
CRC treatment (20, 21). 5-FU, as a gold 
chemotherapeutic agent for the treatment of colon 
cancer, has capability to invade both healthy and 
cancerous cells, therefore its use can be associated 
with side effects (22).  
In this context, Kensara et al. studied on  whether 
TQ may increase chemopreventive feature of 5-FU 
to eliminate the early stages of CRC and explained 
its mechanism  in colorectal tumorigenesis induced 
by azoxymethane (AOM) in rat. Greatly, 5-FU/TQ 
compound therapy caused to an more important 
decrease colorectal tumors induced by  AOM and 
large improper crypts foci than individual drugs 
therapy. Mechanistically, TQ and 5- F U 
significantly collaborated to suppress the 
expression of procancerous wingless integration 
(Wnt), nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB), β-catenin, inducible 
nitric oxide synthase (iNOS), cyclooxygenase 
(COX-2), VEGF and thiobarbituric acid reactive 
substances (TBRAS) and increase anti-
tumorigenesis transforming growth factor beta 
(TGF-β1), TGF-βRII, Dickkopf-1 (DKK-1), 
CDNK-1A, glutathione peroxidase (GPx) and 
Smad4 expression. This study was the first report 
which explained the in vivo increase feature of 
composed 5-FU and TQ against early stages of 
CRC (23).  
The other study was done to survey the effect of 
preserved drug release of 5-FU, TQ and 
Epigallocatechin-3-gallate (EGCG) on the 
metabolic action and also morphological 
alternations in the SW-626 human colon cancer 
cell line in culture. The findings showed that 
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preserved drug release of TQ and EGCG had 
marked cellular damages and intervention of 
cellular metabolic actions. Also, glutathione, 
malondialdehyde (MDA) and nitric oxide showed 
important changes at 24 hours. Structurally, 
cellular alternations happened following exposure 
to TQ and EGCG as early as 24 hours that were 
similar to cells exposed to 5-FU, too. According to 
this study, using of natural compound such as TQ 
can be offer for treatment of colon cancer (24). 
In the other study, therapeutic effect of TQ on two 
different mice colon cancer, was studied. In 
addition, it investigated the effect of TQ on the 
C26 mouse colorectal carcinoma spheroids 
development and evaluated tumor invasion in vitro. 
Intraperitoneally injection of TQ, importantly 
decreased the sizes and numbers of aberrant crypt 
foci (ACF) and also tumor multiplicity. 
Additionally, this study showed that sub-cyto-toxic 
doses of TQ (40μM) reduced C26 cell invasion and 
repressed 3-dimensional spheroids growth. 
Morphologically, apoptotic figures were 
importantly raised in spheroids treated with TQ 
(25). 
Another investigation showed that TQ caused to 
apoptosis in human colon cancer HCT116 cells by 
inactivation of STAT3 through stopping JAK2-and 
Src mediated phosphorylation of EGF receptor 
tyrosine kinase (26). 
Zhang and Colleague, investigated features and 
molecular activity of TQ on colon cancer cells. 
Findings indicated that TQ treatment importantly 
reduced cell viability in HCT116 and COLO205 
cells, in a dose dependent way. In addition, 
sensitivity of HCT116 and COLO205 cells to 
cisplatin treatment was increased by TQ treatment 
in a concentration-dependent way. Determination 
of the phosphorylated p65 and NF-κB-regulated 
gene products, c-Myc and Bcl-2 and vascular 
endothelial growth factor (VEGF) was done by 
western blot analysis. The findings showed that 
TQ treatment importantly reduced phosphorylated 
p65 level in the nucleus, that exhibited the 
prevention of NF-Κb action by TQ. TQ treatment 
reduced c-Myc, Bcl-2 and VEGF levels 
expression. Also, prevention of NF-κB activity 
with particular preventer, powered the induction of 
cell death and resulted to a chemosensitization 
property of TQ in colon cancer cells. According to 
this study, TQ could induce cell death and 
chemosensitized colon cancer cells through 
prevention of NF-κB signaling (27). 
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Topotecan as topoisomerase I inhibitor, is an 
anticancer drug which is widely applied in the 
treatment of ovarian, lung, breast and colorectal 
adenocarcinoma. Because of myelosuppressive 
feature of topotecan which is related to its  
primary dose-limiting toxicity, there are research 
to recognize  other chemotherapeutic compounds  
which  can synergistically act with topotecan to 
enhance  its effect and decrease its toxicity. Some 
studies have shown that cells which are exposed to 
natural agents for example TQ, followed by 
oxaliplatin or gemcitabine caused to higher growth 
prevention in contrast oxaliplatin or gemcitabine 
treatment alone. Khalife et al. investigated 
mechanism of action of topotecan in the viability 
and apoptotic ways in human colon cancer cell 
lines in contrast to TQ, to find the antiproliferative 
and proapoptotic properties of TQ on the effect of 
the topotecan as a chemotherapeutic agent, and to 
study the powered synergistic property of TQ with 
topotecan. The results showed that both drugs 
caused to apoptosis by a p53-independent pathway 
but the p21 expression was only occurred in 
treatment with TQ. Stop in cell cycle in the S 
phase was found with each matter separately, 
whereas combined treatment caused to enhance in 
fragmented DNA production. Induce in apoptosis 
through the extrinsic way was done by both 
compounds after 24 hours; whereas, after 48 
hours, activation of the intrinsic pathway was seen 
by treatment with topotecan only. According to 
this study, TQ enhanced the effectiveness of 
topotecan as a chemotherapeutic reagent through 
preventing of proliferation and decreasing toxicity 
through p53- and Bax/Bcl2-independent 
mechanisms (28). 
COX-2 as an enzyme, has a role to the transform 
of  arachidonic acid into PGE2 which can increase 
expression of COX-2 protein and tumor cell 
multiplication. The study by Hsu et al. showed that 
TQ (20 μmol/L) importantly decreased human 
LoVo colon cancer cell proliferation and migration 
through decreasing prostaglandin E2 induced 
COX-2 activation (29). 
Other study surveyed pre- and post- treatment of 
TQ on oxidative stress induced by 1,2-dimethyl-
hydrazine (DMH) during beginning and 
development of colon carcinogenesis in rats. Pre-
treatment with TQ (5mg/kg) ameliorated entirely 
oxidative stress induced by DMH at beginning and 
established histological alternations and tumor 
promotion. Additionally, it abolished oxidative 
stress aggravation at beginning, and importantly 
decreased tumour occurrence. In contrast, post-
treatment with TQ (5mg/kg) restored oxidative 
status and reduced tumour promotion at beginning. 
It decreased MDA and antioxidant content at 
promotion slightly with a little decrease in tumour 
status and dysplasia level. This investigation 
showed effectiveness of TQ in protecting and 
treatment DMH-induced beginning phase of colon 
cancer and also protective role at promotion. This 
study supported the idea that TQ may be as a 
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chemo-preventive agent in colorectal cancer (30).  
Occurrence of colorectal cancer in people with 
familial adenomatous polyposis (FAP) is high. In 
the study by Lang et al. chemopreventive features 
of TQ on FAP were evaluated in mice. TQ 
treatment (375 mg/kg but not 37.5 mg/kg) reduced 
large polyp's numbers in the small intestine of 
mice. TQ caused to apoptosis in the neoplastic 
mucosa but not in the normal tissue. In addition, 
treatment with TQ, retained β-catenin at the 
membrane and reduced c-myc in the nucleus that 
was accompanied with a decreased cell 
multiplication in the villi. Also, activation of GSK-
3β which induced membranous localization of β-
catenin and decreased expression of nuclear c-myc 
was done by TQ treatment. This study showed that  
TQ interfered with polyp development in mice by 
induction of specific apoptosis of tumor-cell and 
through modulating Wnt signaling by GSK-3β 
activation and according to these results, TQ might 
be effective agent as nutritional complement  to 
surgery and chemoprevention in FAP (31). 
Recently investigations have showed the anticancer 
properties of Vitamin D3 (Vit.D) and TQ. 
Evaluation of  synergistic potential of TQ and 
Vit.D in the control of colon cancer development 
which was induced by  azoxymethane in rat model, 
was done. The results indicated that combination of 
TQ and Vit.D (4 weeks before to induction and 
continued for a total of 20 week) had an important 
anti- tumor property  in contrast to each of them 
lonely which was showed by great decrease of the 
grown tumors numbers and major improper crypts 
foci.  In addition, gene expression and/or protein 
quantification findings showed a great  reduction of   
pro-cancerous molecules (β-catenin, NF-κB, iNOS, 
Wnt, VEGF, COX-2 and heat shock protein 90 
(HSP-90) and also a great increase of anti-
tumorigenesis biomarkers (DKK-1, TGF-β1, 
smad4, CDNK-1A and TGF-β/RII) in contrast  to 
un-supplemented or individually supplemented 
groups, respectively. According to this study, TQ 
increased the chemopreventive property of Vit.D 
during the beginning phase of colon cancer in rat 
with the possible to repress development of pre-
neoplastic injuries in colon carcinogenesis (32). 
Table 1 provides a brief summary of the anti- 
cancer activity of TQ against alimentary canal 
cancers. 
Liver cancer 
Liver cancer accounts 5th the most common 
malignancy universal and the 3th leading cause of 
death.  Hepatocellular carcinoma (HCC) is 
responsible for about 80-90% of all liver cancer 
and accounts as the 4th most common reason of 
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Animal/Cell Mechanism Ref. 
Oral cancer cells 
(T28) 
Eesophageal 
carcinoma cell 
  
Ggastric cancer cells, 
Xenograft tumor 
mouse model 
  
Human gastric cancer 
cells (HGC27), 
xenograft tumor in 
mice model 
  
  
Rat colorectal cancer 
  
  
  
SW-626 human colon 
cancer cell line 
  
  
C26 mouse colorectal 
carcinoma spheroids 
  
Human colon cancer 
HCT116 cells 
  
  
Colon cancer cells 
  
  
  
Human colon cancer 
cell lines 
 
 
  
Human LoVo colon 
cancer cell 
  
 
  
Colon carcinogenesis 
in rats 
  
  
  
Mice 
  
 
  
Colon cancer in rat 
Increased apoptosis (down regulation  of p38β MAPK) 
  
Enhanced chemosensitivity and cellular apoptosis of DDP (blocking the activation of 
JAK2/STAT3 way) 
  
Elevated  the apoptotic features in gastric cancer cells induced by 5-FU  (decreasing of 
bcl-2, increasing of bax as well as caspase-3 and caspase-9 activation) 
  
 
Caused to apoptotic cell death, prevented the STAT3 phosphorylation, decreased the 
STAT3-regulated genes expression including cyclin D, survivin, Bcl-2, and VEGF, and 
activated caspase-3,7,9. 
  
5-FU/TQ compound caused to  an more important decrease  colorectal tumors and 
large improper crypts foci than individual drugs therapy, 5-FU/TQ significantly 
collaborated to suppress the expression of procancerous Wnt, NF-κB, β-catenin, iNOS, 
COX-2, VEGF and TBRAS and increase anti-tumorigenesis TGF-β1, TGF-βRII, DKK
-1, CDNK-1A, GPx and Smad4 expression. 
 
Cellular damages and intervention of cellular metabolic actions 
 
 
 
Decreased the sizes and numbers of ACF and tumor  multiplicity, reduced C26 cell 
invasion and repressed three-dimensional spheroids Growth 
 
Caused to apoptosis (inactivation of STAT3 through stopping JAK2-and Src mediated 
phosphorylation of EGF receptor tyrosine kinase) 
 
 
Reduced  cell viability in HCT116 and COLO205 cells, reduced phosphorylated p65 
level in the nucleus, prevention of NF-Κb action, reduced c-Myc, Bcl-2 and VEGF 
levels expression, powered  the induction of cell death 
 
Enhanced the effectiveness of topotecan as a the chemotherapeutic reagent (preventing 
of  proliferation and decreasing toxicity through p53- and Bax/Bcl2-independent 
mechanisms) 
 
Decreased human LoVo colon cancer cell proliferation and migration (decreasing 
prostaglandin E2 induced COX-2 activation) 
 
 
Ameliorated entirely oxidative stress induced by DMH at beginning and stable histo-
logical alternations and tumor promotion, abolished oxidative stress aggravation at 
begining, decreased tumour occurrence 
 
 
Interfered with polyp development in mice (induction of specific apoptosis of tumor-
cell and through modulating Wnt signaling) 
 
Increased the chemopreventive property of Vit.D during the beginning phase of colon 
cancer, decreased of the grown tumors numbers and   major improper crypts foci, 
reduction of   pro-cancerous molecules (β-catenin, NF-κB, iNOS, Wnt, VEGF, COX-2 
and HSP-90), a great increase of anti-tumorigenesis biomarkers (DKK-1, TGF-β1, 
smad4, CDNK-1A and TGF-β/RII) 
(13) 
  
(14) 
  
  
(18) 
  
  
 
(19) 
  
 
 
(23) 
  
 
 
 
 
(24) 
  
 
 
(25) 
  
  
 (26) 
  
  
  
(27) 
  
  
  
(28) 
  
  
  
(29) 
  
  
 
  
( 30) 
  
 
 
 
 
(31) 
  
  
 
  
(32) 
  
Table 1.  Effect of TQ on alimentary canal cancer  
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cancer mortality. However there are various planes 
for liver cancer treatment, chemoprevention 
appears to be the best plan for decrease the 
occurrence of this disease (33, 34). 
In HCC, interleukin-8 (IL-8) is increased, therefore 
it is considered as a target for treatment. However 
the transcription factor NF-κB adjusts expression 
of IL-8, and while TQ prevents NF-κB activity. 
The careful mechanisms that with them TQ 
regulates IL-8 and cancer cell proliferation remain 
to be explained.  Ashour et al. reported that TQ 
prevented HCC cells proliferation in a dose and 
time dependent way, resulted to  G2M cell cycle 
stop, and motivated apoptosis. Treatment with TQ 
inhibited  NF-κB expression and repressed  IL-8 
and its receptors. Also, treatment with TQ resulted 
to enhanced levels of ROS and genes involved in 
oxidative stress. Pretreatment of HepG2 cells with 
N-acetylcysteine as a remover of ROS, inhibited 
TQ-induced cell death. TQ increased mRNA 
expression of pro-apoptotic Bcl-xS, and prevented 
expression of the anti-apoptotic gene Bcl-2. TQ 
increased TRAIL-induced death of HepG2 cells, 
partly through increasing in TRAIL death 
receptors, preventing IL-8 and NF-κB and inducing 
apoptosis. Generally, this study provided views 
into the molecular mechanisms of TQ-dependent 
repression of HCC cell proliferation and 
emphasized its ability as anti-HCC drug (35).  
The other study, investigated antitumor activity of 
TQ through examination of its effect on cell cycle, 
angiogenesis, and apoptosis. The findings showed 
the ability of TQ as an antitumor agent against 
various types of cancer such as colon, brain, cervix, 
and liver at both a time- and concentration-
dependent way. It induced G2/M phase cell cycle 
stop in HepG2 cells, and a concentration-dependent 
development in the number of apoptotic cells with 
an elevation in the ratio of Bax/BCL-2. 
Furthermore, mRNA expression and protein level 
of VEGF reduced when the concentration of TQ 
elevated. The data of this study indicated an 
increase in the  glutathione content and phase II 
enzyme GST activity in HepG2 cells. This study, 
supported the beneficial effect of TQ as a 
chemopreventive and therapeutic agent against liver 
cancer (36). 
Sayed-Ahmed et al. investigated whether TQ could 
inhibit beginning of hepatocarcinogenesis which 
was induced by diethylnitrosamine (DENA) as a 
strong initiator and hepatocarcinogen in rat model. 
Administration of TQ (4 mg/kg/day, orally) 
completely corrected biochemical and 
histopathological alternations following DENA 
injection to the control values. The findings of this 
study suggested reduced mRNA expression of 
glutathione peroxidase (GSHPx), catalase (CAT) 
and glutathione-s-transferase (GST) during DENA-
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induced beginning of hepatic carcinogenesis that 
TQ supplementation inhibited the progression of 
DENA-induced initiation of liver cancer through 
reducing oxidative stress and maintaining the 
mRNA expression of GSHPx and CAT and activity 
of antioxidant enzymes (37). 
Agents that prevent cell multiplication and limit 
hepatic tumorigenesis by cell cycle adjustment 
have a positive property in the HCC treatment. 
Raghunandhakumar and colleaguees  investigated 
the effect of TQ on N-nitrosodiethylamine (NDEA)
- induced hepatocarcinogenesis in rat. TQ (20 mg/
kg) treatment markedly  decreased  liver damage 
markers and reduced tumor markers and inhibited 
hepatic nodule formation and decreased  tumor 
proliferation in  liver cancer induced by NDEA 
which was obvious from argyrophilic nucleolar 
organizer region (AgNORs) dying.  In addition, 
TQ treatment importantly decreased  adverse 
changes   through stopping of cell proliferation that 
greatly  caused to G1/S stop in the cell cycle  
transmission. According to this study, TQ has a 
potential anti proliferative effect through adjusting 
the G1/S phase cell cycle transmission  and 
showed a beneficial effect  in the HCC treatment 
(38). 
Table 2 provides a brief summary of the anti- 
cancer activity of TQ against hepatic cancers.  
Pancreatic cancer  
Pancreatic cancer which is known as one of the 
most fatal cancers in the world, keeps on to be 
resistant to any treatment approaches. 
Banerjee et al. for the first time, investigated  
chemosensitizing effect of TQ to  ordinary 
chemotherapeutic agents by application of an 
orthotopic model of pancreatic cancer both in vitro 
and in vivo. In vitro findings showed that 
preexposure of cells with TQ (25 mumol/L) for 48 
hours after oxaliplatin  or gemcitabine caused to in 
60% to 80% development prevention in contrast to 
15% to 25% when oxaliplatin  or gemcitabine was 
applied alone. Also, TQ could power the pancreatic 
cancer cells death which was induced by 
chemotherapeutic agents through down-regulation 
of NF-kB, NF-kB-dependent antiapoptotic genes 
and Bcl-2 family. In addition, markedly, TQ was 
able to decrease in NF-kB (which gets activated on 
exposure of pancreatic cancer cells to ordinary 
chemotherapeutic agents) in vitro, causing in 
chemosensitization. In addition, in vitro findings 
indicated that TQ with oxaliplatin and/or 
gemcitabine is much further helpful as an 
antitumor agent in contrast to either agent alone. 
According to this study, particular target, such as 
NF-kB, was inactivated in animal tumors which 
was pretreated by TQ after oxaliplatin and/or 
gemcitabine. These results explained that TQ can 
cancel oxaliplatin and/or gemcitabine induced 
activation of NF-kB, causing to in the 
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chemosensitization of pancreatic tumors to usual 
therapeutics (39). 
In the other study, Yusufi  and colleagues indicated 
high anti-proliferative effect, superior chemo-
sensitizing activity of TQ analogs against 
pancreatic cancer in vitro and in mixed with 
Gemcitabine as  an effective drug in pancreas 
cancer treatment (40). 
In pancreatic cancer, the expression of high 
molecular weight glycoprotein mucin 4 (MUC4) is 
increased which has role in the regulation of 
growth, differentiation, metastasis, and the 
chemoresistance of PC cells. Prevention of MUC4 
expression in the normal pancreatic ductal cells is a 
promising target for new cancer therapies. In this 
context, Torres et al. investigated TQ effect on PC 
cells and particularly evaluated  its effect on 
MUC4 expression. The results showed that TQ 
treatment decreased expression  of MUC4 through 
the proteasomal way and caused to apoptosis in PC 
cells. Reduce in MUC4 expression associated with 
an increase in apoptosis, reduced motility, and 
reduced emigration of PC cells. According to this 
study, TQ has potential effect for the development 
of new treatment against pancreatic cancer (41). 
Other study surveyed the anti-metastatic property 
of TQ on the pancreatic cancer both in vitro and in 
vivo. The findings indicated that TQ repressed the 
emigration and invasion of Panc-1 cells does-
dependently. TQ greatly decreased matrix 
metallopeptidase 9 (MMP-9) and NF-kB  in Panc-1 
cells. Also, TQ administration significantly 
decreased tumor metastasis in contrast to untreated 
control in metastatic model induced in mice. In 
addition to, MMP-9 and NF-kB  expression was 
suppressed following TQ treatment. The findings 
of this study indicated that TQ has  anti-metastatic 
activity on pancreatic cancer both in vitro and in 
vivo, that possibly related to decrease in  NF-kB  
expression and its regulated molecules such as 
MMP-9 protein. Based on  these results, TQ could 
be introduced as an antimetastatic agent human 
pancreatic cancer  treatment (42). 
Inflammation has been introduced as an important 
factor in increase of the solid tumour malignancies. 
Pancreatic ductal adenocarcinoma (PDAC) is 
almost resistant to the treatments.  Chronic 
pancreatitis including both congenital and sporadic 
are related to an enhanced risk of increasing PDA. 
Chehl et al. indicated that TQ  caused to apoptosis 
and prevented  PDA cells proliferation. In addition, 
the findings of this study showed antiinflammatory 
properties of TQ in PDA cells. According to these 
findings, TQ as a new preventer of 
proinflammatory pathways has a good strategy that 
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mixes anti-inflammatory and proapoptotic modes 
of activity (43). 
Other study surveyed antineoplastic effect of TQ 
in human PDAC cell lines, MiaPaCa-2 and AsPC-
1. TQ (10-50 μM) prevented cell viability and 
multiplication and resulted partial G2 cycle stop in 
dependently dose manner in both cell lines. 
Accumulation of the cells in subG0/G1 phase, 
showing apoptosis. This was related to  increase of 
p53 and decrease of Bcl-2. In vivo, TQ greatly 
decreased tumor size in 67% of defined tumor 
xenograft. This study exhibited that TQ mediated 
posttranslational regulation of histone acetylation, 
prevented expression of HDACs, and caused to 
proapoptotic signaling ways. The mentioned 
molecular targets show reason for application of 
TQ as a promising antineoplastic agent to inhibit 
postoperative cancer return and to delay viability 
of PDAC patients after operation resection (44). 
The study was done by Wang  showed the anti-
neoplastic and anti-metastatic properties of TQ  on 
the human pancreatic carcinoma in nude mice and 
it explained that these effects may be related to the 
decrease in expressions of XIAP and MMP-9 (45).   
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Table 2. Effect of TQ on liver cancer 
Animal/Cell Mechanism Ref. 
  
Human 
hepatocellular 
carcinoma cell 
  
  
 
HepG2 cells 
  
  
 
Rat 
  
  
  
  
  
Rat 
Prevented HCC cells proliferation, resulted to  G2M cell cycle stop, and motivated apoptosis, 
inhibited  NF-κB expression and repressed  IL-8 and its receptors, enhanced levels of ROS 
and genes involved in oxidative stress, increased mRNA expression of pro-apoptotic Bcl-xS, 
and prevented expression of the anti-apoptotic gene Bcl-2 
 
Induced G2/M phase cell cycle stop, developed the number of apoptotic cells with an eleva-
tion in the ratio of Bax/BCL-2, reduced mRNA expression and protein level of VEGF 
 
 
Inhibited the progression of DENA-induced initiation of liver cancer (reducing oxidative 
stress and maintaining   mRNA expression of GSHPx and CAT and activity of antioxidant 
enzymes) 
 
Decreased  liver damage markers and reduced tumor markers and inhibited hepatic nodule 
formation and decreased  tumor proliferation in  liver cancer induced by NDEA, decreased  
adverse changes   (stopping of cell proliferation that greatly  caused to G1/S stop) 
 
(35) 
  
  
  
(36) 
  
  
  
  
(37) 
  
  
  
(38) 
www.thecancerpress.com 
www.imaqpress.com  
 
Vol. 3, No. 4, Dec, 2017 
Shaterzadeh and Noorrbakhsh 2017. The Cancer Press, 3(4): 146-158                                                                                               158    
Animal/Cell Mechanism Ref. 
PC  cell, 
pancreatic cancer 
in mice 
  
  
PC cells 
   
  
PC cells 
  
  
  
Panc-1 cells,  
Metastatic model 
induced in mice 
  
  
PDA cells 
  
 
  
 
Human PDA, 
In vivo 
  
  
   
Human pancreatic 
carcinoma in 
nude mice 
Powered the pancreatic cancer cells death which was induced by chemotherapeutic agents 
(down-regulation of  NF-κB ,  NF-κB -dependent antiapoptotic genes and Bcl-2 family) 
 
 
Anti-proliferative effect, superior chemo-sensitizing activity 
  
Decreased  expression  of MUC4 through the proteasomal way and caused to apoptosis,  
reduced motility, and reduced emigration of PC cells 
  
Repressed the emigration and invasion of Panc-1 cells, decreased MMP-9 and  NF-κB in 
Panc-1 cells. Also, TQ administration significantly decreased tumor metastasis, suppressed 
MMP-9 and  NF-κB expression 
 
  
Caused to apoptosis and prevented  PDA cells proliferation, it showed  antiinflammatory 
properties in   PDA cells 
  
Prevented cell viability and multiplication and resulted partial G2 cycle stop, acumulation 
of the cells in subG0/G1 phase, showing apoptosis (increase of p53 and decrease of Bcl-2), 
decreased tumor size, inhibition of histone deacetylation,  caused to proapoptotic signaling 
ways 
 
Showed anti-neoplastic and anti-metastatic properties (decrease in expressions of XIAP 
and MMP-9) 
(39) 
  
 
 
  
(40) 
  
  
(41) 
  
  
 
(42) 
  
  
 
  
(43) 
  
  
  
 
(44) 
  
  
  
   
(45) 
Table 3. Effect of TQ on pancreatic cancer 
Conclusion 
Medicinal plants have been used as a curative treatment agent for their many benefits such as ability to treat 
diseases including cancers. TQ (active constituent of N. sativa) has been considered in traditional medicine 
for treating different cancers related to GI system. This review indicated the in vitro and in vivo anti- cancer 
activity of TQ associated with its possible mechanisms  in GI  cancers including oral cancer, esoghageal 
cancer, gastric cancer, colorectal cancer and also liver and pancreatic cancers. The different mechanisms of 
anticancer effects of TQ including cell cycle arrest, suppression of cell proliferation and differentiation, 
increasing apoptosis in the cells by increasing of BAX and p53 expression and downregulation of  Bcl-2 and 
Bcl-xl and decreased cells viability. According to this review  TQ and/or its analogues can act as an 
anticancer agent alone or in combination with chemotherapeutic drugs  in treatment of GI tract 
cancers,  however well designed clinical trials in humans are required to confirm these effects. 
